A New Generation of
Periodontal Treatment
ProEncia Biotechnology is introducing a line of novel therapeutics to treat and prevent the entire spectrum of periodontal disease
An Under-Treated Condition
Periodontal disease is the most common disease in the world.
According to the World Health Organization (WHO), over 1 billion people suffer from severe cases globally. In the United States alone, over 50% of adults suffer from some level of periodontal disease.
Emerging research has also linked periodontal disease with enhanced risk of Alzheimer's, dementia, heart disease, lung disease, poorer COVID outcomes and immune system compromise, and other comorbidities.
The ProEncia Approach
For decades, periodontal care has focused on treating isolated indicators (such as plaque and calculus) while leaving the underlying condition largely unaddressed.
ProEncia aims to change this. Our unique approach targets the entire disease and underlying chronic state, underpinned by our team’s deep knowledge of chronic inflammatory diseases and years of groundbreaking pharmaceutical research.
Our goal is to commercialize a treatment that is safer and more effective than any currently available on the market.